Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synteni Inc.

Division of Incyte Corp.

Latest From Synteni Inc.

Zyomyx Inc.

Formed in 1998 by four Stanford scientists, Zyomyx is focusing on the development of microfabricated biochips containing active proteins for use in drug discovery and other potential diagnostic applications.
BioPharmaceutical Medical Device

Chutzpah: Millennium Takes on Diagnostics

Millennium is turning its business development skills on diagnostics, promising to create a high margin business in what has been a price-cutter's paradise. Its advantage: using the discovery infrastructure built at Millennium and financed by drug companies for their deals with Millennium on drug discovery. All Millennium claims that it needs to make diagnostics pay (it hasn't for the vast majority of other diagnostics start-ups) is funding from diagnostics companies and drug firms interested in pursuing pharmacogenomics. Its major competition, the joint venture between SmithKline and Incyte called diaDexus, is skeptical that diagnostic firms, which have hitherto spent their R&D budgets on developing new instrument platforms, not the high risk hunt for new diagnostic markers, will change their tune now, and spend more on biological research than they ever have before by signing deals with Millennium. But Millennium is convinced that without the kind of new, important and expensive diagnostics it can discover with its biotech platform, such traditional diagnostic firms will continue to merely grind their profitability down in price wars.
BioPharmaceutical Medical Device

Genomic Solutions Inc.

GSI has developed a system combining DNA chip production and analysis with proteomics tools to provide an integrated drug discovery solution to pharmaceutical and biotech customers.
BioPharmaceutical Platform Technologies

Illumina Inc.

Start-up company Illumina Inc. is developing a platform that uses fiber optic beaded array technology for genomics, proteomics, pharmaceutical screening, medical diagnostics, and optical olfaction.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Randall S Livingston, CFO
    Dari Shalon, PhD, Pres.
    Mark W Schwartz, PhD, VP, Mktg. & Bus. Dev.
    Howard D Goldstein, VP, Sales & Customer Service
    Keith Love, VP, Operations
  • Contact Info
  • Synteni Inc.
    Phone: (510) 739-2100
    6519 Dumbarton Cir.
    Fremont, CA 94555
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register